Akura Medical, a privately held portfolio company of Shifamed LLC, is a medical technology company dedicated to addressing venous thromboembolism (VTE). Our flagship product, the Katana Thrombectomy System, is poised to redefine pulmonary embolism (PE) treatment standards by enabling removal of diverse clot types more efficiently. The Katana Thrombectomy System embodies our mission to reshape the landscape of VTE care and make a lasting impact on the lives of patients worldwide.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/01/25 | $53,000,000 | Series C |
Qatar Investment Authority | undisclosed |
